Ontology highlight
ABSTRACT:
SUBMITTER: Mittal K
PROVIDER: S-EPMC3873008 | biostudies-other | 2012
REPOSITORIES: biostudies-other
Mittal Kriti K Wood Laura S LS Rini Brian I BI
Biologics in therapy 20121016
Targeted agents have revolutionized the management of metastatic renal cell carcinoma (RCC). Axitinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR), has been an important addition to currently available therapies for advanced RCC. Its ability to inhibit VEGFRs at nanomolar concentrations distinguishes it as a potent tyrosine kinase inhibitor, with increased selectivity for VEGFR-1, 2, and 3 at clinically applicable concentrations. The phase 3 AXIS trial has established its ...[more]